Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ofranergene obadenovec + paclitaxel
- Development stage
- Unknown
- Lead developer
- VBL Therapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules, Gene Therapies
- Administration
- Intravenous
01
Overview
Ofranergene obadenovec (VB-111, also known as ofra-vec) is a non-replicating adenoviral vector-based gene therapy designed for cancer treatment. It carries a pro-apoptotic human Fas-chimera transgene under the control of a modified murine PPE-1-3x promoter and is specifically expressed in angiogenic endothelial cells. The drug exerts dual mechanisms—vascular disruption (anti-angiogenesis) and immune activation—by inducing apoptosis in tumor vasculature and stimulating CD8+ T-cell infiltration into tumors[1][4][5]. Paclitaxel is a standard chemotherapeutic agent that stabilizes microtubules, inhibiting cell division. The combination has been investigated primarily for recurrent platinum-resistant ovarian cancer in multiple phase III clinical trials[1][5][8]. Ofranergene obadenovec was developed by VBL Therapeutics.
- Other names
- ofranergene obadenovec + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))CXADR (Coxsackievirus and adenovirus receptor)
Beyond the preview
Go deeper on ofranergene obadenovec + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ofranergene obadenovec + paclitaxel.